Cargando…

Effectiveness and safety of 99Tc-methylene diphosphonate as a disease-modifying anti-rheumatic drug (DMARD) in combination with conventional synthetic (cs) DMARDs in the treatment of rheumatoid arthritis: A systematic review and meta-analysis of 34 randomized controlled trials

BACKGROUND: Technetium [99Tc] methylene diphosphonate injection (99Tc-MDP) is widely used for the treatment of rheumatoid arthritis (RA), but there is still insufficient evidence for its application. Through the utilization of meta-analysis and systematic reviews, this study aimed to evaluate the ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Guoqian, Chen, Xinyi, Shao, Le, Wu, Qibiao, Wang, Shenzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628711/ https://www.ncbi.nlm.nih.gov/pubmed/37942155 http://dx.doi.org/10.1016/j.heliyon.2023.e21691

Ejemplares similares

Idiopathic Hepatic and Splenic Uptake of (99m)Tc-Methylene Diphosphonate
por: Kalimuthu, Lokeshwaran Madurai, et al.
Publicado: (2020)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Evaluation of Finger Blood Flow with Tc-99m MDP (methylene diphosphonate)
por: Bang, Shin Ho, et al.
Publicado: (1992)

Incidental Tc-99m Methylene Diphosphonate Uptake in an Active Thyroid Nodule
por: Çayır, Derya, et al.
Publicado: (2017)

Metastatic superscan on (99m)Tc-methylene diphosphonate bone scintigraphy in pediatric neuroblastoma
por: Arora, Saurabh, et al.
Publicado: (2015)

Extraosseous (99m)Tc-methylene diphosphonate uptake on bone scan: Unusual scenario
por: Verma, Shashwat, et al.
Publicado: (2016)

Bone turnover markers are correlated with total skeletal uptake of (99m)Tc-methylene diphosphonate ((99m)Tc-MDP)
por: Lenora, Janaka, et al.
Publicado: (2009)

Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?
por: Lwin, May, et al.
Publicado: (2020)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Extraosseous accumulation of bone scan tracer (99m)Tc-methylene diphosphonate in a phlebolith
por: Kulkarni, Mukta, et al.
Publicado: (2012)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

Jaffe–Campanacci syndrome: Any role for (99m)Tc-methylene diphosphonate bone and (99m)Tc-octreotide scans for evaluation of the disorder?
por: Qutbi, Mohsen, et al.
Publicado: (2019)

Radiographically Occult Latent Radiogenic Osteosarcoma Uncovered on Tc-99m Methylene-diphosphonate Bone Scintigraphy
por: Jolepalem, Prashant, et al.
Publicado: (2013)

Extraosseous Tc-99m methylene diphosphonate concentration in the forearm following post-mastectomy lymphatic obstruction
por: Bhattacharya, Anish, et al.
Publicado: (2012)

Marked gastric uptake of Tc-99m methylene diphosphonate (MDP) in a patient with myeloma and hypercalcemia
por: Foley, Kieran, et al.
Publicado: (2015)

Compression of (99m)Tc Methylene Diphosphonate Bone Scan Images using Discrete Cosine Transformation
por: Pandey, Anil Kumar, et al.
Publicado: (2022)

(99m)Tc-methylene diphosphonate SPECT/CT imaging of gout spondylitis: a case report
por: Wang, Yan, et al.
Publicado: (2022)

The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice
por: Roberts, Lynden, et al.
Publicado: (2017)

Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
por: Mueller, Ruediger B., et al.
Publicado: (2019)

‘Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?’
por: Goodman, Susan M, et al.
Publicado: (2020)

Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study
por: Iwamoto, Naoki, et al.
Publicado: (2022)

Non-osseous uptake on Tc99m methylene diphosphonate in multiple muscles confirmed on SPECT/computed tomography
por: Tarsarya, Sunita, et al.
Publicado: (2012)

Extra-osseous (99m)Tc methylene diphosphonate uptake detected enlargement of the knee joint in patient with polyarthritis
por: Caprio, Maria Grazia, et al.
Publicado: (2017)

Suprapatellar bursitis presenting as unilateral “Hot” patella sign on (99m)Tc-methylene diphosphonate skeletal scintigraphy
por: Kousik, Vankadari, et al.
Publicado: (2021)

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2023)

Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis
por: Peterson, Jeffrey D, et al.
Publicado: (2010)

Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort
por: Lukas, Cédric, et al.
Publicado: (2019)

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
por: Wang, Susan Siyu, et al.
Publicado: (2023)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
por: Tsai, Jih-Jin, et al.
Publicado: (2023)

Hepatic metastasis arising from diverse primary pathologies diagnosed on 99mTc-Methylene diphosphonate bone scan
por: Narayan, M. L., et al.
Publicado: (2015)

Is 99m Tc-methylene diphosphonate bone scintigraphy a sensitive method for detecting bone lesions in multiple myeloma?
por: Vakili Sadeghi, Mohsen, et al.
Publicado: (2018)

Biological or targeted synthetic DMARDs increase COVID-19 severity
Publicado: (2021)

Are DMARDs enough to prevent surgery in rheumatoid hands?
por: Sim, Yeap Swan
Publicado: (2015)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Establishment and verification of a nomogram and a preliminary study on predicting the clinical response of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis patients
por: Sun, Zhijian, et al.
Publicado: (2022)

A double-blind, double-dummy, randomized controlled, multicenter trial of (99)Tc-methylene diphosphonate in patients with moderate to severe rheumatoid arthritis
por: Fu, Qiong, et al.
Publicado: (2021)

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis
por: Verstappen, M., et al.
Publicado: (2020)

A history of the term “DMARD”
por: Buer, Jonas Kure
Publicado: (2015)

(99m)TC-Methylene diphosphonate uptake at injury site correlates with osteoblast differentiation and mineralization during bone healing in mice
por: Zhong, Zhendong A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1cfmvjstefnkhf9h4tp1thmrs6